Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 3, 2000, Pages 221-226

  Shulman, Nancy S ^a   Zolopa, Andrew R ^a   Passaro, Douglas J ^a   Murlidharan, Usha ^a   Israelski, Dennis M ^a   Brosgart, Carol L ^b   Miller, Michael D ^b   Van Doren, Sälly ^b   Shafer, Robert W ^a   Katzenstein, David A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Adefovir; Efavirenz; Genotype; Salvage therapy; Virologic response

Indexed keywords

ADEFOVIR DIPIVOXIL; EFAVIRENZ;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE;

EID: 12944314948     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200003010-00002     Document Type: Article

References (19)

1. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279:930-7.
2. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73.
3. Murphy RL, Katlama C, Johnson V, et al. A randomized, openlabel trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data [abstract LB 19]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, U.S.A., 1999.
4. Richman DD, Havlir D,Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy. J Virol 1994;68:1660-66.
5. Byrnes VW, Sardana VV, Schleif WA, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1575-9.
6. Richman DD, of Shih C-K, Lowy I, et al. Human immunodeficiency virus type I mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-15.
7. Demeter LM, Shafer RW, Para M, et al. Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy (ACTG 260) [abstract 23].4th International Workshop on HIV Drug Resistance, Sardinia, 1995.
8. Dueweke TJ, Pushkarskays T, Poppe SM, et-al. A mutation in reverse transcriptase of big (heteraryl) piperazine-resistant human immunodeficiency virus type I that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90: 4713-17.
9. Demeter LM, Meehan PM, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:136-44.
10. Jeffrey S, Baker D, Tritch R, et al. Resistance profile for Sustiva (efavirenz, DMP266) [abstract 702]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1998.
11. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates form individuals who were switched to other protease inhibitors after long term saquinavir treatment. J Virol 1998;72:5303-6.
12. Hammond J, Calef C, Larder B, Schinazi R, Mellors JW. Mutations in retroviral genes associated with drug resistance. In: Korber BT, Kuiken C, Foley B, et al., eds. Human Retroviruses and AIDS: a compilation and analysis of nucleic and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory, 1998.
13. Hirsch MS, Conway B, DAquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998;279:1984-91.
14. Masur H, Falloon J, Thomas D, et al. Durability of abacavir/ amprenavir/efavirenz combination salvage therapy - preliminary 48-week response (CNA2007) [abstract 206]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, 1999.
15. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type I RNA load and appearance of drug-resistance populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-19.
16. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′deoxy-3′thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
17. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr 1995; 10(Suppl 1):S28-33.
18. Miller MD, Anton KE, Mulato AS, et al. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999;179:1, 92-100.
19. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12.